drugset / Trial / NCT00038090

Thalidomide-Dexamethasone for Multiple Myeloma

NCT00038090

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.

Timeline

Start
2000-06
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 20 mg/m2 Oral
Subject Thalidomide Other / unclassified 100 mg Oral

Indications